Also observed with PD-1/PD-L1 blockers, hyper progressive disease (HPD) is characterized by accelerated tumor proliferation, high metastatic burden, and early death (mean overall survival of 3.4 months) within the first two months of treatment. Here, CD274 is linked to neoplasm.